|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These include: (1) the intra-renal renin-angiotensin system (RAS), one based on molecular variations in angiotensinogen; (2) the Na, K, 2Cl cotransporter (NKCC2) and its regulators in the thick ascending limb, which are associated with a variety of phenotypes consistent with a more active cotransporter in blacks; and (3) the genes for MYH9 and APOL 1, which have been associated with kidney disease in blacks.
|
23397215 |
2013 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The findings suggest that the AGT T235 allele is a determinant of the nephropathy susceptibility related to type 2 diabetes in these aboriginal Canadians.
|
10383081 |
1999 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II and aldosterone are the main effectors of the renin-angiotensin aldosterone system (RAAS) and have a central role in hypertension as well as cardiovascular and renal disease.
|
31425690 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To assess the antiproteinuric response to multifactorial treatment based on high doses of angiotensin II receptor antagonists (ARBs) (olmesartan) in patients with non-diabetic proteinuric nephropathies, according to three renin-angiotensin system (RAS) polymorphisms: insertion/deletion of the angiotensin converting enzyme (ACE) gene, the angiotensinogen gene M235T and the angiotensin II type 1 receptor (AT1R) A1166C.
|
24241364 |
2013 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The data present the first evidence that thromboxane receptor inhibition ameliorates angiotensin II-induced nephropathy.
|
17890857 |
2008 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this meta-analysis, we attempted to derive pooled estimates for the putative associations between various cardiovascular-renal disorders and the M235T polymorphism of the angiotensinogen gene.
|
10100088 |
1999 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II, the most vasoactive component of the renin-angiotensin-aldosterone (RAAS) pathway, can contribute to renal disease by causing an increase in arterial blood pressure leading to glomerular injury and fibrosis.
|
18206321 |
2008 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
To investigate predictive genetic markers for diabetic nephropathy, we studied the genetic polymorphisms of angiotensin-converting enzyme (ACE) and angiotensinogen (AGN) in Japanese subjects with non-insulin-dependent diabetes mellitus (NIDDM) with and without nephropathy.
|
8596493 |
1996 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our study provided evidence against an association between angiotensinogen M235T or chymase gene CMA/B polymorphisms and the presence of incipient or overt nephropathy in Caucasian patients with type II diabetes.
|
11096141 |
2000 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II) contributes to the progression of renal diseases associated with proteinuria and glomerulosclerosis mainly by inducing podocyte apoptosis.
|
30005635 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The importance of the RAS in the development and pathogenesis of cardiovascular, hypertensive and kidney diseases has now been firmly established in clinical trials and practice using renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, type 1 (AT<sub>1</sub>) angiotensin II (ANG II) receptor blockers (ARBs), or aldosterone receptor antagonists as major therapeutic drugs.
|
28619367 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.
|
17989111 |
2008 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we used angiotensin II (AngII) infusion (2.1 mg/kg/day for 2 wk) in mice as a second model to confirm and extend our observations on the beneficial effects of CSD on heart and kidney disease.
|
30576317 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.
|
30992195 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recently, the angiotensinogen (AGT) gene, M235T, and angiotensin II type 1 receptor (ATR) gene, A1166C, polymorphisms have been associated with the susceptibility to develop hypertension and renal disease.
|
12950120 |
2003 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Among 574 972 patients with diabetes mellitus from 259 US practices, median (interquartile range) achievement of the quality metrics across the practices was the following: (1) glycemic control: 19% (5-47); (2) blood pressure control: 80% (67-88); (3) angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in patients with coronary artery disease: 62% (51-69); (4) nephropathy screening: 62% (53-71); (5) eye examination: 0.7% (0.0-79); (6) foot examination: 0.0% (0.0-2.3); and (7) tobacco screening/cessation counseling: 86% (80-94).
|
28862933 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II receptor antagonists, NF-ĸB inhibitors, thiazide diuretics, and antimetabolic drugs can reduce renal macrophage infiltration and slow down the progression of renal disease by mechanisms independent of those usually attributed to these compounds.
|
31649546 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy.
|
21500980 |
2011 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In a hospital cohort study, we examined whether or not ACE (Angiotensin-I converting enzyme) and AGT (Angiotensinogen) gene polymorphisms were associated with the development of nephropathy in long-term Japanese insulin-dependent diabetes mellitus (IDDM) patients with or without proliferative retinopathy, and whether or not the polymorphisms were associated with an arteriosclerotic family history in first degree relatives of the patients.
|
10499884 |
1999 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are guideline-recommended agents to prevent development and progression of nephropathy and cardiovascular diseases in diabetes mellitus (DM).
|
28816537 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Pro-inflammatory role of angiotensin II in mercuric chloride-induced nephropathy in rats.
|
22822941 |
2013 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Limited evidence exists on the choice of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in diabetic patients with nephropathy.
|
28618426 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We have previously suggested that the angiotensinogen 235T variant may be associated with nephropathy in diabetic Chinese.
|
11200871 |
2001 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
1.The role of the renin-angiotensin system (RAS) in cardiac hypertrophy and nephropathy was examined in Tsukuba hypertensive mice (THM) carrying both human renin and angiotensinogen genes.2.
|
10081615 |
1999 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
C57BL/6 mice were treated with angiotensin II by subcutaneous infusion for 1 month to develop nephropathy.
|
30958891 |
2019 |